A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence

Journal of Cutaneous Medicine and Surgery
Yves PoulinAditya K Gupta

Abstract

Moderate to severe plaque psoriasis has traditionally been treated with agents that have toxicities associated with long-term use. Many patients therefore cannot be treated safely, conveniently or effectively with traditional therapies. Recent phase 3 clinical trials for efalizumab, a biological agent targeted specifically at the T-cell-based pathology of psoriasis, have demonstrated its short- and long-term efficacy and safety for the treatment of psoriasis. This article reviews results from 12-week, six-month, and three-year trials, focusing on the drug's safety, efficacy, and therapeutic response time, as well as the phenomenon of rebound in non-responding patients. Efalizumab emerges as an important addition to the dermatological pharmacopeia for the long-term treatment of psoriasis.

References

Mar 29, 2003·Expert Opinion on Biological Therapy·Jennifer Clay CatherAlan Menter
Jul 4, 2003·The Journal of Investigative Dermatology·Heinrich DickelThomas L Diepgen
Aug 2, 2003·Journal of the American Academy of Dermatology·Craig L Leonardi
Nov 25, 2003·The New England Journal of Medicine·Mark LebwohlUNKNOWN Efalizumab Study Group
Dec 18, 2003·JAMA : the Journal of the American Medical Association·Kenneth B GordonUNKNOWN Efalizumab Study Group
Apr 13, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·M Clemons
May 22, 2004·Journal of the American Academy of Dermatology·Christopher S CarlinGerald G Krueger
Sep 29, 2004·Dermatologic Clinics·Craig L Leonardi
Mar 12, 2005·Journal of the American Academy of Dermatology·Craig L LeonardiUNKNOWN Efalizumab Study Group
Apr 1, 2005·American Journal of Clinical Dermatology·Keri Wellington, Caroline M Perry
Apr 19, 2005·Expert Opinion on Biological Therapy·Jennifer Clay Cather, Alan Menter
Sep 27, 2005·The British Journal of Dermatology·M de GrootJ D Bos
Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Neil H ShearVincent Ho

❮ Previous
Next ❯

Citations

Mar 16, 2017·Mitochondrial DNA. Part A. DNA Mapping, Sequencing, and Analysis·Nilkantha ChatterjeeSankar Kumar Ghosh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.